These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 6786914)

  • 1. Effects of dihydroergocriptine on mouse and rat resistance to acute anoxia: influence of repetition of treatment.
    Legeai JM; Benharkate MM; Duverger JP; Boulu RG
    Experientia; 1981 Mar; 37(3):292-3. PubMed ID: 6786914
    [No Abstract]   [Full Text] [Related]  

  • 2. [Pathopharmacologic models of cerebral disorders].
    Cahn J
    Med Klin; 1979 Oct; Suppl():25-8. PubMed ID: 575559
    [No Abstract]   [Full Text] [Related]  

  • 3. Synergistic interactions between piracetam and dihydroergocristine in some animal models of cerebral hypoxia and ischaemia.
    Berga P; Beckett PR; Roberts DJ; Llenas J; Massingham R
    Arzneimittelforschung; 1986 Sep; 36(9):1314-20. PubMed ID: 3098253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of indeloxazine hydrochloride (YM-08054) on anoxia.
    Yamamoto M; Shimizu M
    Arch Int Pharmacodyn Ther; 1987 Apr; 286(2):272-81. PubMed ID: 3592867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-hypoxic potency of cerebroprotective drugs studied in a model of acute reversible respiratory failure.
    Tkácová R; Tomori Z; Nistiarová A
    Biomed Biochim Acta; 1989; 48(7):465-71. PubMed ID: 2803283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Action of a permanent magnetic field in compression of the carotid arteries and asphyxia (an experimental study)].
    Rutsaĭ SV
    Vopr Kurortol Fizioter Lech Fiz Kult; 1982; (3):15-8. PubMed ID: 7113035
    [No Abstract]   [Full Text] [Related]  

  • 7. Biochemical and behavioural effects of hypoxic hypoxia in rats: study of the protection afforded by ergot alkaloids.
    Boismare F; Le Poncin M; Lefrançois J
    Gerontology; 1978; 24 Suppl 1():6-13. PubMed ID: 412730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of some ergot alkaloids on the cerebral reduced glutathione.
    Gorini A; Arnaboldi R; Vercesi L; Dossena M
    Farmaco Sci; 1988 Nov; 43(11):887-90. PubMed ID: 3150835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The treatment of posthypoxic encephalopathy in suicide patients by hyperbaric oxygenation].
    Kharchenko EN
    Lik Sprava; 1995; (3-4):165-7. PubMed ID: 8819956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Normobaric hyperoximia increases hypoxia-induced cerebral injury: DTI study in rats.
    Bockhorst KH; Narayana PA; Dulin J; Liu R; Rea HC; Hahn K; Wosik J; Perez-Polo JR
    J Neurosci Res; 2010 Apr; 88(5):1146-56. PubMed ID: 19885827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of some of the pharmacological properties of the new eburnamenine derivative vindeburnol with those of vincamine, vinburnine, dihydroergotoxine mesilate and nicergoline.
    Barzaghi F; Dragonetti M; Formento ML; Gueniau C; Nencioni A; Mantegazza P
    Arzneimittelforschung; 1986 Oct; 36(10):1442-8. PubMed ID: 3814205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of anoxia on the developing cerebral cortex in the rat.
    HICKS SP; CAVANAUGH MC; O'BRIEN ED
    Am J Pathol; 1962 Jun; 40(6):615-35. PubMed ID: 13907195
    [No Abstract]   [Full Text] [Related]  

  • 13. Dihydroergocriptine in management of microprolactinomas.
    Faglia G; Conti A; Muratori M; Togni E; Travaglini P; Zanotti A; Mailland F
    J Clin Endocrinol Metab; 1987 Oct; 65(4):779-84. PubMed ID: 3116032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of dihydroergot alkaloid on experimental brain anoxia. Observations by tissue culture method and isolated perfusion method (author's transl)].
    Saji S; Misao A; Kagawa Y; Hosono K; Sumi Y; Omae K; Yamada H; Kunieda T; Sakata K
    No To Shinkei; 1978 Jan; 30(1):81-90. PubMed ID: 637957
    [No Abstract]   [Full Text] [Related]  

  • 15. [Biological foundations of geriatric pharmacotherapy].
    Zakowska-Wachelko B
    Pol Tyg Lek; 1979 Jun; 34(24):967-9. PubMed ID: 382141
    [No Abstract]   [Full Text] [Related]  

  • 16. Neuroprotective activity of alpha-dihydroergocryptine in animal models.
    Coppi G
    J Neural Transm Suppl; 1995; 45():307-18. PubMed ID: 8748639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative effects of dihydroergotoxine (DHET) on CBF and metabolism changes produced by experimental cerebral edema, hypoxia and hypertension.
    Cahn J; Borzeix MG
    Gerontology; 1978; 24 Suppl 1():34-42. PubMed ID: 618778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effectiveness of dehydroergotoxin (Ergocomb) in patients with severe craniocerebral trauma].
    Mühlnickel B; Neumann S
    Anaesthesiol Reanim; 1987; 12(1):35-9. PubMed ID: 3566902
    [No Abstract]   [Full Text] [Related]  

  • 19. [Effects of dihydroergocriptine, a dihydrogenated ergot alkaloid, on cutaneous or visceral capillaries (author's transl)].
    Legeai J; Benharkate M; Boulu R
    Ann Pharm Fr; 1980; 38(3):215-22. PubMed ID: 6775574
    [No Abstract]   [Full Text] [Related]  

  • 20. Single-case study of clinical response to high-dose ergot alkaloid treatment for dementia. Preliminary report.
    Yesavage JA; Tinklenberg JR
    Gerontology; 1981; 27(1-2):76-8. PubMed ID: 7215823
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.